Shares of Vertex fell 12% on the morning of December 19, after the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. The trial, which targeted pain caused by a pinched nerve in the spine, showed no significant difference in pain reduction compared to a placebo. The company also announced plans to proceed with a Phase 3 trial for suzetrigine, a decision that has left some analysts questioning the rationale. One commentator stated on X "Vertex often gets the benefit of the doubt given its track record, but damn, this one is tough to reconcile." The company's announcements come mere days after insider transactions have been reported. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.